Adani Group shares fall on fresh allegation of possible offshore investment
By Steve Goldstein
Adani Group's publicly traded companies slumped in value on Thursday, after a fresh report alleging that the controlling family may have secretly invested in the company's shares.
The allegations, made by the Organized Crime and Corruption Reporting Project and shared with the Financial Times and the Guardian, say that an undisclosed and complex offshore operation in Mauritius propped up shares between 2013 and 2018. The allegations are similar to those made by the short-selling research firm Hindenburg Research, which have been denied by the company.
Adani again rebuffed the claims, saying they were "a rehash of unsubstantiated allegations levelled in the Hindenburg report."
The flagship Adani Enterprises saw a share price decline of 4%, as other Adani companies including Adani Ports and Adani Green Energy also nursed losses.
The Adani group companies have lost over $100 billion since the Hindenburg allegations were first aired, according to MarketWatch calculations.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-31-23 0721ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?